dupilumab vs stapokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: IL-4R-alpha · full Chronic Obstructive Pulmonary Disease pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT03930732 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 939 participants, and its primary clinical endpoint was met: dupilumab significantly reduced moderate or severe COPD exacerbations over 52 weeks. The registry does not report the power or sample-size calculation needed to establish that the trial was adequately powered, so the evidence is graded as moderate rather than strong.
Next expected readout: July 2028 · NCT07587658 (registry estimate)
Reported efficacy
Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) (met)
Result source: NCT04456673
stapokibart
Marketed by Keymed Biosciences and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2032 · NCT06547333 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dupilumab | stapokibart |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.8 vs 1.0−0.2 vs placeboNCT039307321 other result
| —Trial running · NCT06547333 |
| Trough FEV1, change | —Not reported | —Trial running · NCT06547333 |
| SGRQ total, change | -9.7 vs -6.4−3.4 vs placeboNCT039307321 other result
| —Trial running · NCT06547333 |
| TDI focal score | —Not reported | —Trial running · NCT06547333 |
Moderate or severe exacerbations, annualised rate
- dupilumab
- 0.8 vs 1.0−0.2 vs placeboNCT03930732
1 other result
- 0.9 vs 1.3 NCT04456673
- stapokibart
- —Trial running · NCT06547333
Trough FEV1, change
- dupilumab
- —Not reported
- stapokibart
- —Trial running · NCT06547333
SGRQ total, change
- dupilumab
- -9.7 vs -6.4−3.4 vs placeboNCT03930732
1 other result
- -9.8 vs -6.4 NCT04456673
- stapokibart
- —Trial running · NCT06547333
TDI focal score
- dupilumab
- —Not reported
- stapokibart
- —Trial running · NCT06547333
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
stapokibart: no structured comparison results are available for Chronic Obstructive Pulmonary Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dupilumab: 4 of 4 rows · stapokibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dupilumab |
|---|---|
| Dropout rate | 6%300 mg q2wa NCT03930732 · Phase 3 show 1 more result8.9%300 mg q2w NCT04456673 · Phase 3 |
| Discontinued due to AEs | 1.5%300 mg q2wa NCT03930732 · Phase 3 show 1 more result3%300 mg q2w NCT04456673 · Phase 3 |
| Serious AEs | 13.9%300 mg q2wa NCT03930732 · Phase 3 show 1 more result13.9%300 mg q2w NCT04456673 · Phase 3 |
| Most frequent reported AEs | 300 mg q2wa nasopharyngitis 9.6% (placebo 9.6%) headache 8.1% (placebo 7%) upper respiratory tract infection 7.9% (placebo 9.8%) NCT03930732 · Phase 3 show 1 more result300 mg q2w covid-19 9.6% (placebo 7.8%) headache 7.9% (placebo 6.3%) nasopharyngitis 6.8% (placebo 6%) NCT04456673 · Phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dupilumab
show 1 more result
show 31 more results
show 1 more result
show 1 more result
show 22 more results
show 7 more results
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT01949311 · Phase 3 · completed
This was an explicitly described open-label extension enrolling participants from prior dupilumab atopic dermatitis trials, including the SOLO 1 and SOLO 2 programs, with 2,677 participants receiving dupilumab in a single group. The primary outcomes were safety events rather than a comparative efficacy endpoint, and there was no randomization, blinding, or control arm; therefore, the findings provide limited evidence despite the large enrollment. Its registered primary outcome on ClinicalTrials.gov is "Number of Treatment Emergent Adverse Events (TEAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: November 2026 · NCT06389136 (registry estimate)
Reported efficacy
Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 (At week 16): Dupilumab Q2W 40.3% vs Matching Placebo 16.7% (met)
Result source: NCT04417894
stapokibart
Marketed by Keymed Biosciences and partners
NCT05265923 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial in 500 adults with moderate-to-severe atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 16 weeks than those on placebo (66.9% vs 25.8%).
Next expected readout: February 2027 · NCT07106372 (registry estimate)
Reported efficacy
Proportion of subjects achieving EASI-75 at week 18 (Up to week 18); Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline (up to week 18): EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) (met)
Result source: NCT06277765
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dupilumab | stapokibart |
|---|---|---|
| EASI-75 | 62.6% vs 29.6%+33 vs placeboNCT0275564921 other results
| —Not posted · NCT05265923 |
| IGA 0/1 with 2-point improvement | —Trial running · NCT06884891 | —Not posted · NCT05265923 |
| EASI-90 | 35.7% vs 7.6%+28.1 vs placeboNCT0227774310 other results
| —Not posted · NCT05265923 |
| EASI, % change | 0.1% vs 21.7%−21.6 vs placeboNCT0239513331 other results
| —Not posted · NCT05265923 |
EASI-75
- dupilumab
- 62.6% vs 29.6%+33 vs placeboNCT02755649
21 other results
- 38.1% vs 8.2% NCT03054428
- 59.1% vs 29.6% NCT02755649
- 41.5% vs 8.2% NCT03054428
- 53% vs 10.7% NCT03346434
- 62.6% vs 72.4% NCT03738397
- 65.2% vs 21.6% NCT02260986
- 51.3% vs 14.7% NCT02277743
- 44.2% vs 11.9% NCT02277769
- 64.1% vs 21.6% NCT02260986
- 63.9% vs 23.2% NCT02260986
- 68.9% vs 23.2% NCT02260986
- 57.3% vs 14.5% NCT03912259
- 52.5% vs 14.7% NCT02277743
- 48.1% vs 11.9% NCT02277769
- 58% vs 26.4% NCT02755649
- 69.7% vs 26.8% NCT03345914
- 56.5% vs 26.4% NCT02755649
- 67.2% vs 26.8% NCT03345914
- 18.2% vs 44.3% NCT03738397
- 53.6% vs 19.6% NCT02210780
- 60.6% vs 29.2% NCT04033367
- stapokibart
- —Not posted · NCT05265923
IGA 0/1 with 2-point improvement
- dupilumab
- —Trial running · NCT06884891
- stapokibart
- —Not posted · NCT05265923
EASI-90
- dupilumab
- 35.7% vs 7.6%+28.1 vs placeboNCT02277743
10 other results
- 30% vs 7.2% NCT02277769
- 40.2% vs 6% NCT03912259
- 33.2% vs 7.6% NCT02277743
- 30.5% vs 7.2% NCT02277769
- 19% vs 2.4% NCT03054428
- 41.8% vs 7.3% NCT03345914
- 23.2% vs 2.4% NCT03054428
- 25.3% vs 2.8% NCT03346434
- 30.3% vs 7.3% NCT03345914
- 40.3% vs 61.6% NCT03738397
- stapokibart
- —Not posted · NCT05265923
EASI, % change
- dupilumab
- 0.1% vs 21.7%−21.6 vs placeboNCT02395133
31 other results
- 6.8% vs 21.7% NCT02395133
- 3.8% vs 21.7% NCT02395133
- -84.9% vs -60.9% NCT02260986
- -73.9% vs -39.5% NCT02277743
- -69.6% vs -33.7% NCT02277769
- -80.5% vs -48.4% NCT02260986
- -87.8% vs -60.9% NCT02260986
- -75.2% vs -39.4% NCT03912259
- -75.2% vs -39.4% NCT03912259
- -79.8% vs -46.6% NCT02755649
- -70.4% vs -35.3% NCT03912259
- -65.8% vs -29.4% NCT03912259
- -55.8% vs -19.3% NCT03912259
- -73.8% vs -39.5% NCT02277743
- -71.6% vs -33.7% NCT02277769
- -81.5% vs -48.4% NCT02260986
- -35.7% vs -10.6% NCT03912259
- -64.8% vs -23.6% NCT03054428
- -82.1% vs -48.6% NCT03345914
- -78.2% vs -46.6% NCT02755649
- -65.9% vs -23.6% NCT03054428
- -70% vs -19.6% NCT03346434
- -78.4% vs -48.6% NCT03345914
- -70.5% vs -20.2% NCT01859988
- -74% vs -23.3% NCT01548404
- -75.5% vs -20.2% NCT01859988
- -64.9% vs -20.2% NCT01859988
- -75.2% vs -5.8% NCT01979016
- -67.4% vs -20.2% NCT01859988
- -46.7% vs -20.2% NCT01859988
- -75.6% vs -52.5% NCT01639040
- stapokibart
- —Not posted · NCT05265923
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dupilumab: 4 of 4 rows · stapokibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dupilumab |
|---|---|
| Dropout rate | 51.6%a NCT01949311 · Phase 3 · monotherapy show 51 more results7.1%300 mg q2w NCT02277743 · Phase 3 11.7%300 mg qw NCT02277743 · Phase 3 5.6%300 mg q2w NCT02277769 · Phase 3 7.5%300 mg qw NCT02277769 · Phase 3 12.3%300 mg q2w NCT02260986 · Phase 3 12.9%300 mg qw NCT02260986 · Phase 3 8.3%300 mg Q2W/QW NCT02395133 · Phase 3 11.6%300 mg Q4W NCT02395133 · Phase 3 10.7%300 mg Q8W NCT02395133 · Phase 3 95.2%300 mg Q4W NCT03054428 · Phase 3 —200 mg or 300 mg NCT03054428 · Phase 3 96.3%200 mg or 300 mg Q2W NCT03054428 · Phase 3 n/a: no completion milestone300 mg Q4W NCT03345914 · Phase 3 · combination n/a: no completion milestone100 mg or 200 mg Q2W NCT03345914 · Phase 3 · combination 98.8%200 mg or 300 mg Q4W NCT03346434 · Phase 2/3 · combination 0%6 mg/kg NCT03346434 · Phase 2/3 0%6 mg/kg NCT03346434 · Phase 2/3 0%3 mg/kg NCT03346434 · Phase 2/3 10%3 mg/kg NCT03346434 · Phase 2/3 10.4%Q2W NCT04417894 · Phase 3 3.2% NCT05590585 · Phase 4 · registry result, not featured evidence 17.6% NCT03293030 · Phase 4 · registry result, not featured evidence 29.4% NCT03667014 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participant NCT04718870 · Phase 4 · registry result, not featured evidence 0%Atopic Dermatitis Participants NCT04718870 · Phase 4 · registry result, not featured evidence 20% NCT04823130 · Phase 4 · registry result, not featured evidence —DB Period: Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 3.9%Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence —OLE Period: Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0% NCT04447417 · Phase 4 · registry result, not featured evidence 6.9%300 mg EOW NCT03738397 · Phase 3 · registry result, not featured evidence 7.3%300 mg Q2W NCT03912259 · Phase 3 · registry result, not featured evidence 92.5%300 mg Q2W NCT02755649 · Phase 3 · registry result, not featured evidence · combination 92.7%300 mg QW NCT02755649 · Phase 3 · registry result, not featured evidence · combination 0% NCT03359356 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 8.2%300 mg qw NCT02210780 · Phase 2 · registry result, not featured evidence 3.7%200 mg qw NCT01979016 · Phase 2 · registry result, not featured evidence 18.8%300 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 15.4%300 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 17.5%300 mg qw NCT01859988 · Phase 2 · registry result, not featured evidence 45.2%200 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 35.4%100 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 25.5%300 mg NCT01548404 · Phase 2 · registry result, not featured evidence —300 mg NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy 0%300 mg QW NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | 4%a NCT01949311 · Phase 3 · monotherapy show 51 more results2.7%300 mg q2w NCT02277743 · Phase 3 2.7%300 mg qw NCT02277743 · Phase 3 0.9%300 mg q2w NCT02277769 · Phase 3 1.7%300 mg qw NCT02277769 · Phase 3 0%300 mg q2w NCT02260986 · Phase 3 3.4%300 mg qw NCT02260986 · Phase 3 0%300 mg Q2W/QW NCT02395133 · Phase 3 3.5%300 mg Q4W NCT02395133 · Phase 3 1.2%300 mg Q8W NCT02395133 · Phase 3 —300 mg Q4W NCT03054428 · Phase 3 —200 mg or 300 mg NCT03054428 · Phase 3 —200 mg or 300 mg Q2W NCT03054428 · Phase 3 —300 mg Q4W NCT03345914 · Phase 3 · combination —100 mg or 200 mg Q2W NCT03345914 · Phase 3 · combination —200 mg or 300 mg Q4W NCT03346434 · Phase 2/3 · combination —6 mg/kg NCT03346434 · Phase 2/3 —6 mg/kg NCT03346434 · Phase 2/3 —3 mg/kg NCT03346434 · Phase 2/3 —3 mg/kg NCT03346434 · Phase 2/3 —Q2W NCT04417894 · Phase 3 — NCT05590585 · Phase 4 · registry result, not featured evidence — NCT03293030 · Phase 4 · registry result, not featured evidence — NCT03667014 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participant NCT04718870 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participants NCT04718870 · Phase 4 · registry result, not featured evidence — NCT04823130 · Phase 4 · registry result, not featured evidence —DB Period: Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0.8%Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence —OLE Period: Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence — NCT04447417 · Phase 4 · registry result, not featured evidence 0.9%300 mg EOW NCT03738397 · Phase 3 · registry result, not featured evidence 4.9%300 mg Q2W NCT03912259 · Phase 3 · registry result, not featured evidence —300 mg Q2W NCT02755649 · Phase 3 · registry result, not featured evidence · combination —300 mg QW NCT02755649 · Phase 3 · registry result, not featured evidence · combination — NCT03359356 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 5.2%300 mg qw NCT02210780 · Phase 2 · registry result, not featured evidence 3.7%200 mg qw NCT01979016 · Phase 2 · registry result, not featured evidence 1.6%300 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 1.5%300 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 3.2%300 mg qw NCT01859988 · Phase 2 · registry result, not featured evidence 4.8%200 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 3.1%100 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 1.8%300 mg NCT01548404 · Phase 2 · registry result, not featured evidence —300 mg NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy 0%300 mg QW NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
| Serious AEs | 10.6%a NCT01949311 · Phase 3 · monotherapy show 51 more results3.1%300 mg q2w NCT02277743 · Phase 3 0.9%300 mg qw NCT02277743 · Phase 3 2.5%300 mg q2w NCT02277769 · Phase 3 3.8%300 mg qw NCT02277769 · Phase 3 3.6%300 mg q2w NCT02260986 · Phase 3 3.8%300 mg qw NCT02260986 · Phase 3 3.6%300 mg Q2W/QW NCT02395133 · Phase 3 4.6%300 mg Q4W NCT02395133 · Phase 3 3.6%300 mg Q8W NCT02395133 · Phase 3 0%300 mg Q4W NCT03054428 · Phase 3 0%200 mg or 300 mg NCT03054428 · Phase 3 —200 mg or 300 mg Q2W NCT03054428 · Phase 3 2.5%300 mg Q4W NCT03345914 · Phase 3 · combination 0%100 mg or 200 mg Q2W NCT03345914 · Phase 3 · combination 0%200 mg or 300 mg Q4W NCT03346434 · Phase 2/3 · combination 0%6 mg/kg NCT03346434 · Phase 2/3 0%6 mg/kg NCT03346434 · Phase 2/3 10%3 mg/kg NCT03346434 · Phase 2/3 10%3 mg/kg NCT03346434 · Phase 2/3 4.5%Q2W NCT04417894 · Phase 3 5.6% NCT05590585 · Phase 4 · registry result, not featured evidence 0% NCT03293030 · Phase 4 · registry result, not featured evidence 0% NCT03667014 · Phase 4 · registry result, not featured evidence 0%Atopic Dermatitis Participant NCT04718870 · Phase 4 · registry result, not featured evidence —Atopic Dermatitis Participants NCT04718870 · Phase 4 · registry result, not featured evidence 3.2% NCT04823130 · Phase 4 · registry result, not featured evidence 1.6%DB Period: Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence —Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0.8%OLE Period: Dupilumab/Dupilumab NCT04033367 · Phase 4 · registry result, not featured evidence 0% NCT04447417 · Phase 4 · registry result, not featured evidence 2.1%300 mg EOW NCT03738397 · Phase 3 · registry result, not featured evidence 1.2%300 mg Q2W NCT03912259 · Phase 3 · registry result, not featured evidence 1.9%300 mg Q2W NCT02755649 · Phase 3 · registry result, not featured evidence · combination 2.7%300 mg QW NCT02755649 · Phase 3 · registry result, not featured evidence · combination 2.5% NCT03359356 · Phase 2 · registry result, not featured evidence 5%4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 10.5%4 mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence —4mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 5%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 0%2mg/kg NCT02407756 · Phase 2 · registry result, not featured evidence 3.1%300 mg qw NCT02210780 · Phase 2 · registry result, not featured evidence 0%200 mg qw NCT01979016 · Phase 2 · registry result, not featured evidence 3.1%300 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 4.6%300 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 1.6%300 mg qw NCT01859988 · Phase 2 · registry result, not featured evidence 1.6%200 mg q2w NCT01859988 · Phase 2 · registry result, not featured evidence 7.7%100 mg q4w NCT01859988 · Phase 2 · registry result, not featured evidence 1.8%300 mg NCT01548404 · Phase 2 · registry result, not featured evidence 0%300 mg NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy —300 mg QW NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | a nasopharyngitis 28.9% dermatitis atopic 16.7% upper respiratory tract infection 13.6% NCT01949311 · Phase 3 · monotherapy show 44 more results300 mg q2w dermatitis atopic 15.3% (placebo 29.7%) nasopharyngitis 11.8% (placebo 9.9%) headache 9.2% (placebo 5.9%) NCT02277743 · Phase 3 300 mg qw injection site reaction 18.8% (placebo 5.9%) nasopharyngitis 11.9% (placebo 9.9%) dermatitis atopic 9.6% (placebo 29.7%) NCT02277743 · Phase 3 300 mg q2w dermatitis atopic 14.4% (placebo 35%) injection site reaction 13.6% (placebo 6.4%) nasopharyngitis 9.7% (placebo 10.7%) NCT02277769 · Phase 3 300 mg qw dermatitis atopic 16.5% (placebo 35%) injection site reaction 13.1% (placebo 6.4%) headache 9.7% (placebo 5.1%) NCT02277769 · Phase 3 300 mg q2w dermatitis atopic 36.4% (placebo 51.1%) nasopharyngitis 23.6% (placebo 19.7%) injection site reaction 14.5% (placebo 7.6%) NCT02260986 · Phase 3 300 mg qw dermatitis atopic 28.9% (placebo 51.1%) nasopharyngitis 20% (placebo 19.7%) injection site reaction 19% (placebo 7.6%) NCT02260986 · Phase 3 300 mg Q2W/QW dermatitis atopic 20.4% (placebo 48.8%) nasopharyngitis 19.2% (placebo 13.4%) upper respiratory tract infection 7.8% (placebo 7.3%) NCT02395133 · Phase 3 300 mg Q4W dermatitis atopic 34.5% (placebo 48.8%) nasopharyngitis 12.6% (placebo 13.4%) bronchitis 5.7% (placebo 1.2%) NCT02395133 · Phase 3 300 mg Q8W dermatitis atopic 32.1% (placebo 48.8%) nasopharyngitis 13.1% (placebo 13.4%) upper respiratory tract infection 8.3% (placebo 7.3%) NCT02395133 · Phase 3 300 mg Q4W dermatitis atopic 19.3% (placebo 24.7%) nasopharyngitis 12% (placebo 4.7%) upper respiratory tract infection 8.4% (placebo 17.6%) NCT03054428 · Phase 3 200 mg or 300 mg dermatitis atopic 18.3% (placebo 24.7%) upper respiratory tract infection 12.2% (placebo 17.6%) headache 11% (placebo 10.6%) NCT03054428 · Phase 3 300 mg Q4W nasopharyngitis 12.5% (placebo 6.7%) upper respiratory tract infection 11.7% (placebo 10%) dermatitis atopic 6.7% (placebo 14.2%) NCT03345914 · Phase 3 · combination 100 mg or 200 mg Q2W upper respiratory tract infection 9.8% (placebo 10%) dermatitis atopic 8.2% (placebo 14.2%) nasopharyngitis 6.6% (placebo 6.7%) NCT03345914 · Phase 3 · combination 200 mg or 300 mg Q4W dermatitis atopic 14.5% (placebo 30.8%) nasopharyngitis 8.4% (placebo 9%) upper respiratory tract infection 6% (placebo 9%) NCT03346434 · Phase 2/3 · combination 6 mg/kg nasopharyngitis 20% (placebo 9%) cough 10% (placebo 6.4%) dermatitis atopic 10% (placebo 30.8%) NCT03346434 · Phase 2/3 6 mg/kg cough 10% (placebo 6.4%) nasopharyngitis 10% (placebo 9%) skin abrasion 10% (placebo 0%) NCT03346434 · Phase 2/3 3 mg/kg pyrexia 20% (placebo 9%) constipation 10% (placebo 0%) cough 10% (placebo 6.4%) NCT03346434 · Phase 2/3 3 mg/kg dermatitis atopic 10% (placebo 30.8%) impetigo 10% (placebo 7.7%) nasopharyngitis 10% (placebo 9%) NCT03346434 · Phase 2/3 Q2W nasopharyngitis 23.9% (placebo 12.1%) covid-19 16.4% (placebo 21.2%) upper respiratory tract infection 10.4% (placebo 4.5%) NCT04417894 · Phase 3 eye irritation 35.3% oral/facial herpes simplex 17.6% covid19 (moderate) 5.9% NCT03293030 · Phase 4 · registry result, not featured evidence eye redness 2.9% eyelid swelling 2.9% facial erythema 2.9% NCT03667014 · Phase 4 · registry result, not featured evidence dermatitis atopic 39.1% medical device site haemorrhage 26.1% upper respiratory tract infection 17.4% NCT04718870 · Phase 4 · registry result, not featured evidence headache 22.6% dermatitis atopic 9.7% conjunctivitis 6.5% NCT04823130 · Phase 4 · registry result, not featured evidence conjunctivitis 9.4% (placebo 4.9%) headache 7.1% (placebo 8.2%) dermatitis atopic 3.1% (placebo 13.1%) NCT04033367 · Phase 4 · registry result, not featured evidence accidental overdose 12.3% (placebo 0%) conjunctivitis 2.5% (placebo 4.9%) dermatitis atopic 2.5% (placebo 13.1%) NCT04033367 · Phase 4 · registry result, not featured evidence injection site reaction 19.2% arthralgia 11.5% food allergy 7.7% NCT04447417 · Phase 4 · registry result, not featured evidence 300 mg EOW conjunctivitis 10.6% dermatitis atopic 9.7% nasopharyngitis 8.2% NCT03738397 · Phase 3 · registry result, not featured evidence 300 mg Q2W dermatitis atopic 43.9% (placebo 49.4%) upper respiratory tract infection 17.1% (placebo 12%) protein urine present 11% (placebo 10.8%) NCT03912259 · Phase 3 · registry result, not featured evidence 300 mg Q2W nasopharyngitis 20.6% (placebo 16.7%) conjunctivitis allergic 15% (placebo 6.5%) conjunctivitis 11.2% (placebo 3.7%) NCT02755649 · Phase 3 · registry result, not featured evidence · combination 300 mg QW nasopharyngitis 16.4% (placebo 16.7%) headache 10% (placebo 9.3%) conjunctivitis allergic 9.1% (placebo 6.5%) NCT02755649 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 15% (placebo 10%) other orthopedic injuries/procedures 12.5% (placebo 5%) conjuctivitis 10% (placebo 0%) NCT03359356 · Phase 2 · registry result, not featured evidence 4 mg/kg nasopharyngitis 40% dermatitis atopic 15% abdominal pain upper 10% NCT02407756 · Phase 2 · registry result, not featured evidence 4 mg/kg nasopharyngitis 52.6% cough 36.8% dermatitis atopic 26.3% NCT02407756 · Phase 2 · registry result, not featured evidence 2mg/kg dermatitis atopic 10% influenza 10% nasopharyngitis 10% NCT02407756 · Phase 2 · registry result, not featured evidence 2mg/kg dermatitis atopic 27.8% nasopharyngitis 27.8% cheilitis 5.6% NCT02407756 · Phase 2 · registry result, not featured evidence 300 mg qw upper respiratory tract infection 11.3% (placebo 14.4%) conjunctivitis 8.2% (placebo 0%) headache 5.2% (placebo 3.1%) NCT02210780 · Phase 2 · registry result, not featured evidence 200 mg qw dermatitis atopic 14.8% (placebo 14.8%) upper respiratory tract infection 14.8% (placebo 14.8%) nasopharyngitis 11.1% (placebo 18.5%) NCT01979016 · Phase 2 · registry result, not featured evidence 300 mg q2w nasopharyngitis 25% (placebo 26.2%) dermatitis atopic 20.3% (placebo 16.4%) upper respiratory tract infection 9.4% (placebo 18%) NCT01859988 · Phase 2 · registry result, not featured evidence 300 mg q4w nasopharyngitis 32.3% (placebo 26.2%) dermatitis atopic 15.4% (placebo 16.4%) headache 7.7% (placebo 3.3%) NCT01859988 · Phase 2 · registry result, not featured evidence 300 mg qw nasopharyngitis 25.4% (placebo 26.2%) dermatitis atopic 12.7% (placebo 16.4%) headache 12.7% (placebo 3.3%) NCT01859988 · Phase 2 · registry result, not featured evidence 200 mg q2w nasopharyngitis 26.2% (placebo 26.2%) headache 14.8% (placebo 3.3%) dermatitis atopic 13.1% (placebo 16.4%) NCT01859988 · Phase 2 · registry result, not featured evidence 100 mg q4w nasopharyngitis 30.8% (placebo 26.2%) dermatitis atopic 16.9% (placebo 16.4%) headache 10.8% (placebo 3.3%) NCT01859988 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 40% (placebo 18.5%) headache 16.4% (placebo 13%) conjunctivitis 14.5% (placebo 3.7%) NCT01548404 · Phase 2 · registry result, not featured evidence 300 mg nasopharyngitis 23.8% (placebo 20%) headache 14.3% (placebo 10%) oropharyngeal pain 14.3% (placebo 10%) NCT01639040 · Phase 2 · registry result, not featured evidence · background therapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dupilumab
show 26 more results
show 19 more results
show 11 more results
show 22 more results
show 26 more results
show 18 more results
+ 127 further endpoints in the CSV export.
Asthma
Shared mechanism: IL-4R-alpha · full Asthma pipeline
dupilumab · Dupixent
Marketed by Regeneron Pharmaceuticals and partners
NCT03782532 · Phase 3 · completed
The study was randomized, triple-blind, and placebo-controlled with 486 participants, which is a substantial and generally rigorous design. The primary endpoint was a lung-function measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.
Next expected readout: December 2026 · NCT05347771 (registry estimate)
Reported efficacy
Change in pre-bronchodilator forced expiratory volume (FEV1) (Baseline to Week 12): Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414). (met)
Result source: NCT03782532
stapokibart
Marketed by Keymed Biosciences and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2032 · NCT05761028 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dupilumab | stapokibart |
|---|---|---|
| Severe exacerbations, annualised rate | 0.5 vs 1.0−0.4 vs placeboNCT024148547 other results
| —Trial running · NCT05761028 |
| Trough FEV1, change | 0.3 vs 0.7−0.4 vs placeboNCT035604665 other results
| —Trial running · NCT05761028 |
| ACQ-5, change | -1.5 vs -1.3−0.2 vs placeboNCT0241485419 other results
| —Trial running · NCT05761028 |
| OCS dose reduction | 70.1% vs 41.9%+28.2 vs placeboNCT025282141 other result
| —Trial running · NCT05761028 |
Severe exacerbations, annualised rate
- dupilumab
- 0.5 vs 1.0−0.4 vs placeboNCT02414854
7 other results
- 0.5 vs 1.0 NCT02414854
- 0.6 vs 1.6 NCT02528214
- 0.5 vs 0.1 NCT03560466
- 0.3 vs 0.9 NCT01854047
- 0.3 vs 0.9 NCT01854047
- 0.6 vs 0.9 NCT01854047
- 0.4 vs 0.9 NCT01854047
- stapokibart
- —Trial running · NCT05761028
Trough FEV1, change
- dupilumab
- 0.3 vs 0.7−0.4 vs placeboNCT03560466
5 other results
- 0.3 vs 0.6 NCT03560466
- 0.1 vs 0.5 NCT03560466
- 0.2 vs 0.4 NCT03560466
- 0.1 vs 0.4 NCT03560466
- 0.1 vs 0.4 NCT03560466
- stapokibart
- —Trial running · NCT05761028
ACQ-5, change
- dupilumab
- -1.5 vs -1.3−0.2 vs placeboNCT02414854
19 other results
- -1.5 vs -1.2 NCT02414854
- -1.4 vs -1.1 NCT02414854
- -1.2 vs -1.1 NCT02414854
- -1.1 vs -0.8 NCT02414854
- -0.9 vs -0.6 NCT02414854
- -1.5 vs -1.3 NCT02414854
- -1.5 vs -1.2 NCT02414854
- -1.3 vs -1.1 NCT02414854
- -1.3 vs -1.1 NCT02414854
- -1.1 vs -0.8 NCT02414854
- -0.9 vs -0.6 NCT02414854
- -0.9 vs -0.6 NCT02528214
- -0.8 vs -0.5 NCT02528214
- -0.9 vs -0.6 NCT02528214
- -0.9 vs -0.5 NCT02528214
- -0.7 vs -0.4 NCT02528214
- -0.6 vs -0.4 NCT02528214
- -0.5 vs -0.2 NCT02528214
- -1.1 vs -0.5 NCT01312961
- stapokibart
- —Trial running · NCT05761028
OCS dose reduction
- dupilumab
- 70.1% vs 41.9%+28.2 vs placeboNCT02528214
1 other result
- 100% vs 50% NCT02528214
- stapokibart
- —Trial running · NCT05761028
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
stapokibart: no structured comparison results are available for Asthma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. dupilumab: 4 of 4 rows · stapokibart: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dupilumab |
|---|---|
| Dropout rate | 7.7%a NCT03560466 · Phase 3 · background therapy show 36 more results—Participants From DRI12544 Study D NCT02134028 · Phase 3 —Participants From DRI12544 Study P NCT02134028 · Phase 3 10%Participants From DRI12544: Dupilu NCT02134028 · Phase 3 8.1%Participants From DRI12544: Placeb NCT02134028 · Phase 3 —Participants From EFC13579 Study D NCT02134028 · Phase 3 —Participants From EFC13579 Study P NCT02134028 · Phase 3 10.4%Participants From EFC13579: Dupilu NCT02134028 · Phase 3 10.1%Participants From EFC13579: Placeb NCT02134028 · Phase 3 —Participants From EFC13691 Study D NCT02134028 · Phase 3 —Participants From EFC13691 Study P NCT02134028 · Phase 3 15.6%Participants From EFC13691: Dupilu NCT02134028 · Phase 3 14.4%Participants From EFC13691: Placeb NCT02134028 · Phase 3 —Participants From PDY14192 Study D NCT02134028 · Phase 3 —Participants From PDY14192 Study P NCT02134028 · Phase 3 21.4%Participants From PDY14192: Dupilu NCT02134028 · Phase 3 21.1%Participants From PDY14192: Placeb NCT02134028 · Phase 3 5.1%300 mg q2w NCT01854047 · Phase 2 8.7%200 mg q2w NCT01854047 · Phase 2 9.6%300 mg q4w NCT01854047 · Phase 2 12.3%200 mg q4w NCT01854047 · Phase 2 8.1%300 mg q2w NCT02414854 · Phase 3 7.1%200 mg q2w NCT02414854 · Phase 3 2.9%300 mg q2w NCT02528214 · Phase 3 —300mg q2w NCT02528214 · Phase 3 3.9%300 mg Q2W NCT04998604 · Phase 4 · registry result, not featured evidence 5.9%200 mg Q2W NCT04502862 · Phase 4 · registry result, not featured evidence 2.8%300 mg Q2W NCT04400318 · Phase 4 · registry result, not featured evidence —300 mg Q2W NCT04203797 · Phase 4 · registry result, not featured evidence 0%Dupilumab NCT04203797 · Phase 4 · registry result, not featured evidence 0% NCT05036733 · Phase 4 · registry result, not featured evidence 4.8% NCT03620747 · Phase 3 · registry result, not featured evidence 25.3%300 mg NCT03387852 · Phase 2 · registry result, not featured evidence —300mg NCT03387852 · Phase 2 · registry result, not featured evidence 36.5%SAR440340 + Dupilumab NCT03387852 · Phase 2 · registry result, not featured evidence · combination 0% NCT02573233 · Phase 2 · registry result, not featured evidence 13.5%300 mg qw NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | 0%a NCT03560466 · Phase 3 · background therapy show 36 more results—Participants From DRI12544 Study D NCT02134028 · Phase 3 —Participants From DRI12544 Study P NCT02134028 · Phase 3 4.5%Participants From DRI12544: Dupilu NCT02134028 · Phase 3 2.7%Participants From DRI12544: Placeb NCT02134028 · Phase 3 —Participants From EFC13579 Study D NCT02134028 · Phase 3 —Participants From EFC13579 Study P NCT02134028 · Phase 3 3.2%Participants From EFC13579: Dupilu NCT02134028 · Phase 3 2.5%Participants From EFC13579: Placeb NCT02134028 · Phase 3 —Participants From EFC13691 Study D NCT02134028 · Phase 3 —Participants From EFC13691 Study P NCT02134028 · Phase 3 5.6%Participants From EFC13691: Dupilu NCT02134028 · Phase 3 4.1%Participants From EFC13691: Placeb NCT02134028 · Phase 3 —Participants From PDY14192 Study D NCT02134028 · Phase 3 —Participants From PDY14192 Study P NCT02134028 · Phase 3 14.3%Participants From PDY14192: Dupilu NCT02134028 · Phase 3 5.3%Participants From PDY14192: Placeb NCT02134028 · Phase 3 2.5%300 mg q2w NCT01854047 · Phase 2 4%200 mg q2w NCT01854047 · Phase 2 6.4%300 mg q4w NCT01854047 · Phase 2 4.5%200 mg q4w NCT01854047 · Phase 2 1.9%300 mg q2w NCT02414854 · Phase 3 1.1%200 mg q2w NCT02414854 · Phase 3 1%300 mg q2w NCT02528214 · Phase 3 —300mg q2w NCT02528214 · Phase 3 1.7%300 mg Q2W NCT04998604 · Phase 4 · registry result, not featured evidence 1%200 mg Q2W NCT04502862 · Phase 4 · registry result, not featured evidence 1.4%300 mg Q2W NCT04400318 · Phase 4 · registry result, not featured evidence —300 mg Q2W NCT04203797 · Phase 4 · registry result, not featured evidence 0%Dupilumab NCT04203797 · Phase 4 · registry result, not featured evidence — NCT05036733 · Phase 4 · registry result, not featured evidence 1.5% NCT03620747 · Phase 3 · registry result, not featured evidence 0%300 mg NCT03387852 · Phase 2 · registry result, not featured evidence —300mg NCT03387852 · Phase 2 · registry result, not featured evidence 2.7%SAR440340 + Dupilumab NCT03387852 · Phase 2 · registry result, not featured evidence · combination — NCT02573233 · Phase 2 · registry result, not featured evidence 5.8%300 mg qw NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy |
| Serious AEs | 30.8%a NCT03560466 · Phase 3 · background therapy show 36 more results10%Participants From DRI12544 Study D NCT02134028 · Phase 3 12.6%Participants From DRI12544 Study P NCT02134028 · Phase 3 —Participants From DRI12544: Dupilu NCT02134028 · Phase 3 —Participants From DRI12544: Placeb NCT02134028 · Phase 3 10.5%Participants From EFC13579 Study D NCT02134028 · Phase 3 9.3%Participants From EFC13579 Study P NCT02134028 · Phase 3 —Participants From EFC13579: Dupilu NCT02134028 · Phase 3 —Participants From EFC13579: Placeb NCT02134028 · Phase 3 11.1%Participants From EFC13691 Study D NCT02134028 · Phase 3 12.4%Participants From EFC13691 Study P NCT02134028 · Phase 3 —Participants From EFC13691: Dupilu NCT02134028 · Phase 3 —Participants From EFC13691: Placeb NCT02134028 · Phase 3 28.6%Participants From PDY14192 Study D NCT02134028 · Phase 3 0%Participants From PDY14192 Study P NCT02134028 · Phase 3 —Participants From PDY14192: Dupilu NCT02134028 · Phase 3 —Participants From PDY14192: Placeb NCT02134028 · Phase 3 8.3%300 mg q2w NCT01854047 · Phase 2 6.8%200 mg q2w NCT01854047 · Phase 2 10.2%300 mg q4w NCT01854047 · Phase 2 4%200 mg q4w NCT01854047 · Phase 2 8.9%300 mg q2w NCT02414854 · Phase 3 8.1%200 mg q2w NCT02414854 · Phase 3 —300 mg q2w NCT02528214 · Phase 3 8.7%300mg q2w NCT02528214 · Phase 3 1.7%300 mg Q2W NCT04998604 · Phase 4 · registry result, not featured evidence 3%200 mg Q2W NCT04502862 · Phase 4 · registry result, not featured evidence 4.2%300 mg Q2W NCT04400318 · Phase 4 · registry result, not featured evidence 0%300 mg Q2W NCT04203797 · Phase 4 · registry result, not featured evidence —Dupilumab NCT04203797 · Phase 4 · registry result, not featured evidence 13.3% NCT05036733 · Phase 4 · registry result, not featured evidence 5.6% NCT03620747 · Phase 3 · registry result, not featured evidence —300 mg NCT03387852 · Phase 2 · registry result, not featured evidence 4.1%300mg NCT03387852 · Phase 2 · registry result, not featured evidence 2.7%SAR440340 + Dupilumab NCT03387852 · Phase 2 · registry result, not featured evidence · combination 5% NCT02573233 · Phase 2 · registry result, not featured evidence 1.9%300 mg qw NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | a pyrexia 46.2% (placebo 2.4%) influenza 38.5% (placebo 5.6%) nasopharyngitis 38.5% (placebo 9.6%) NCT03560466 · Phase 3 · background therapy show 24 more resultsnasopharyngitis 24.3% injection site erythema 23.4% upper respiratory tract infection 16.2% NCT02134028 · Phase 3 300 mg q2w injection site erythema 21.8% (placebo 7.6%) upper respiratory tract infection 12.8% (placebo 17.7%) bronchitis 12.2% (placebo 10.1%) NCT01854047 · Phase 2 200 mg q2w upper respiratory tract infection 14.9% (placebo 17.7%) injection site erythema 14.2% (placebo 7.6%) headache 11.5% (placebo 12.7%) NCT01854047 · Phase 2 300 mg q4w headache 12.1% (placebo 12.7%) nasopharyngitis 12.1% (placebo 9.5%) upper respiratory tract infection 12.1% (placebo 17.7%) NCT01854047 · Phase 2 200 mg q4w upper respiratory tract infection 14.7% (placebo 17.7%) injection site erythema 8.7% (placebo 7.6%) sinusitis 8% (placebo 7%) NCT01854047 · Phase 2 300 mg q2w viral upper respiratory tract infection 17.7% (placebo 19.2%) injection site erythema 15.5% (placebo 4.2%) upper respiratory tract infection 12.2% (placebo 11.8%) NCT02414854 · Phase 3 200 mg q2w viral upper respiratory tract infection 19.2% (placebo 19.2%) injection site erythema 12% (placebo 4.2%) bronchitis 11.6% (placebo 15%) NCT02414854 · Phase 3 300mg q2w viral upper respiratory tract infection 8.7% (placebo 17.8%) bronchitis 6.8% (placebo 5.6%) eosinophil count increased 6.8% (placebo 0%) NCT02528214 · Phase 3 300 mg Q2W nasopharyngitis 11.7% accidental overdose 6.7% headache 5.6% NCT04998604 · Phase 4 · registry result, not featured evidence 200 mg Q2W asthma 9% (placebo 13.9%) nasopharyngitis 4% (placebo 6.9%) NCT04502862 · Phase 4 · registry result, not featured evidence 300 mg Q2W covid-19 9.7% (placebo 8.1%) headache 6.9% (placebo 8.1%) asthma 5.6% (placebo 24.3%) NCT04400318 · Phase 4 · registry result, not featured evidence 300 mg Q2W asthma 5% (placebo 10%) cough 5% (placebo 5%) immunisation reaction 5% (placebo 0%) NCT04203797 · Phase 4 · registry result, not featured evidence asthma 13.2% nasopharyngitis 8.4% covid-19 5.6% NCT03620747 · Phase 3 · registry result, not featured evidence 300mg headache 13.5% (placebo 9.5%) nasopharyngitis 12.2% (placebo 12.2%) rhinitis allergic 6.8% (placebo 1.4%) NCT03387852 · Phase 2 · registry result, not featured evidence nasopharyngitis 10.8% (placebo 12.2%) headache 6.8% (placebo 9.5%) injection site reaction 6.8% (placebo 5.4%) NCT03387852 · Phase 2 · registry result, not featured evidence · combination headache 25% (placebo 13.6%) back pain 15% (placebo 0%) injection site erythema 15% (placebo 9.1%) NCT02573233 · Phase 2 · registry result, not featured evidence 300 mg qw nasopharyngitis 13.5% (placebo 3.8%) upper respiratory tract infection 13.5% (placebo 17.3%) headache 11.5% (placebo 5.8%) NCT01312961 · Phase 2 · registry result, not featured evidence · background therapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dupilumab
show 1 more result
show 7 more results
show 19 more results
show 5 more results
show 19 more results
show 19 more results
show 7 more results
show 7 more results
show 7 more results
+ 111 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dupilumab's landscape · stapokibart's landscape